These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 11992800)

  • 1. Specific targeting of tumor vasculature by diphtheria toxin-vascular endothelial growth factor fusion protein reduces angiogenesis and growth of pancreatic cancer.
    Hotz HG; Gill PS; Masood R; Hotz B; Buhr HJ; Foitzik T; Hines OJ; Reber HA
    J Gastrointest Surg; 2002; 6(2):159-66; discussion 166. PubMed ID: 11992800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of vascular endothelial growth factor blockade and matrix metalloproteinase inhibition as a combination therapy for experimental human pancreatic cancer.
    Hotz HG; Hines OJ; Hotz B; Foitzik T; Buhr HJ; Reber HA
    J Gastrointest Surg; 2003 Feb; 7(2):220-7; discussion 227-8. PubMed ID: 12600446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiogenesis inhibitor TNP-470 reduces human pancreatic cancer growth.
    Hotz HG; Reber HA; Hotz B; Sanghavi PC; Yu T; Foitzik T; Buhr HJ; Hines OJ
    J Gastrointest Surg; 2001; 5(2):131-8. PubMed ID: 11331474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific targeting of tumor endothelial cells by a shiga-like toxin-vascular endothelial growth factor fusion protein as a novel treatment strategy for pancreatic cancer.
    Hotz B; Backer MV; Backer JM; Buhr HJ; Hotz HG
    Neoplasia; 2010 Oct; 12(10):797-806. PubMed ID: 20927318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VEGF antisense therapy inhibits tumor growth and improves survival in experimental pancreatic cancer.
    Hotz HG; Hines OJ; Masood R; Hotz B; Foitzik T; Buhr HJ; Gill PS; Reber HA
    Surgery; 2005 Feb; 137(2):192-9. PubMed ID: 15674201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.
    Bruns CJ; Harbison MT; Davis DW; Portera CA; Tsan R; McConkey DJ; Evans DB; Abbruzzese JL; Hicklin DJ; Radinsky R
    Clin Cancer Res; 2000 May; 6(5):1936-48. PubMed ID: 10815919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo.
    Ramakrishnan S; Olson TA; Bautch VL; Mohanraj D
    Cancer Res; 1996 Mar; 56(6):1324-30. PubMed ID: 8640821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
    Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells.
    Arora N; Masood R; Zheng T; Cai J; Smith DL; Gill PS
    Cancer Res; 1999 Jan; 59(1):183-8. PubMed ID: 9892205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative assessment of angiogenesis and tumor vessel architecture by computer-assisted digital image analysis: effects of VEGF-toxin conjugate on tumor microvessel density.
    Wild R; Ramakrishnan S; Sedgewick J; Griffioen AW
    Microvasc Res; 2000 May; 59(3):368-76. PubMed ID: 10792968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VEGF-RII influences the prognosis of pancreatic cancer.
    Büchler P; Reber HA; Büchler MW; Friess H; Hines OJ
    Ann Surg; 2002 Dec; 236(6):738-49; discussion 749. PubMed ID: 12454512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
    Yano S; Herbst RS; Shinohara H; Knighton B; Bucana CD; Killion JJ; Wood J; Fidler IJ
    Clin Cancer Res; 2000 Mar; 6(3):957-65. PubMed ID: 10741721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the tumor vasculature: inhibition of tumor growth by a vascular endothelial growth factor-toxin conjugate.
    Olson TA; Mohanraj D; Roy S; Ramakrishnan S
    Int J Cancer; 1997 Dec; 73(6):865-70. PubMed ID: 9399667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
    Wood JM
    Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis.
    von Marschall Z; Scholz A; Cramer T; Schäfer G; Schirner M; Oberg K; Wiedenmann B; Höcker M; Rosewicz S
    J Natl Cancer Inst; 2003 Mar; 95(6):437-48. PubMed ID: 12644537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer.
    Dineen SP; Sullivan LA; Beck AW; Miller AF; Carbon JG; Mamluk R; Wong H; Brekken RA
    BMC Cancer; 2008 Nov; 8():352. PubMed ID: 19038046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops.
    Masood R; Kundra A; Zhu S; Xia G; Scalia P; Smith DL; Gill PS
    Int J Cancer; 2003 May; 104(5):603-10. PubMed ID: 12594815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of angiogenesis and tumour growth by VEGF121-toxin conjugate: differential effect on proliferating endothelial cells.
    Wild R; Dhanabal M; Olson TA; Ramakrishnan S
    Br J Cancer; 2000 Oct; 83(8):1077-83. PubMed ID: 10993657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.
    Wedge SR; Ogilvie DJ; Dukes M; Kendrew J; Chester R; Jackson JA; Boffey SJ; Valentine PJ; Curwen JO; Musgrove HL; Graham GA; Hughes GD; Thomas AP; Stokes ES; Curry B; Richmond GH; Wadsworth PF; Bigley AL; Hennequin LF
    Cancer Res; 2002 Aug; 62(16):4645-55. PubMed ID: 12183421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.